LEADER 02994nam 2200505 450 001 9910426052703321 005 20210320035313.0 010 $a3-030-57378-8 024 7 $a10.1007/978-3-030-57378-2 035 $a(CKB)5280000000246082 035 $a(MiAaPQ)EBC6414285 035 $a(DE-He213)978-3-030-57378-2 035 $a(PPN)25250304X 035 $a(EXLCZ)995280000000246082 100 $a20210320d2020 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBone regulators and osteoporosis therapy /$fPaula H. Stern, editor 205 $a1st ed. 2020. 210 1$aCham, Switzerland :$cSpringer,$d[2020] 210 4$dİ2020 215 $a1 online resource (X, 518 p. 1 illus.) 225 1 $aHandbook of Experimental Pharmacology ;$vVolume 262 311 $a3-030-57377-X 327 $aThe cells of bone their interactions -- Parathyroid hormone and bone -- Vitamin D and bone -- Gonadal hormones and bone -- Thyroid hormones, glucocorticoids, insulin, and bone -- Growth factors and bone -- Prostaglandins and bone -- Cytokines and bone: osteoimmunology -- Chemokines and bone -- Calcium and bone -- FGF-23 and bone and mineral metabolism -- Nervous system mediators and bone -- Genetics of bone disorders -- Osteoporosis pathogenesis -- Structural and metabolic assessment of bone status -- Osteoporosis Therapeutics 2019 -- New targets and emergent therapies for osteoporosis -- Drugs causing bone loss -- Natural Products as potential bone therapies. 330 $aThis volume is designed to provide an understanding of current and potential therapies for osteoporosis. The opening chapter introduces the cells of bone and their interactions. Several following chapters describe factors affecting bone including systemic hormones with significant effects on bone, and local mediators including growth factors, prostaglandins, cytokines and chemokines. Topics that have commanded particular attention recently are calcium, FGF-23, nervous system bone interactions. Drugs that cause bone loss provide important information on mechanism as well as therapeutic considerations. An overview of the genetics of bone disorders and a discussion of the pathophysiology of osteoporosis establish the clinical context. The final chapters discuss current and potential osteoporosis treatments. . 410 0$aHandbook of experimental pharmacology ;$vVolume 262. 606 $aOsteoporosis$xTreatment 606 $aOsteoporosis$xPathophysiology 606 $aBones$xPathophysiology 615 0$aOsteoporosis$xTreatment. 615 0$aOsteoporosis$xPathophysiology. 615 0$aBones$xPathophysiology. 676 $a616.716 702 $aStern$b Paula H. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910426052703321 996 $aBone regulators and osteoporosis therapy$91823422 997 $aUNINA